JAZZ PHARMACEUTICALS SOBRE LOS RIESGOS E INCERTIDUMBRES CON LURBINECTEDIN ( ZEPZELCA ) ... : PREVEMOS QUE LURBINECTEDIN ( ZEPZELCA ) COMPITA CON PRODUCTOS GENÉRICOS EN EL FUTURO .
08 diciembre 2008
Velcade . Blood-Cancer Drug Hits $1 Billion .
Year-to-date sales of blood-cancer drug Velcade hit $1 billion in November, indicating the medicine's sales grew more than 25% in a year that saw broadened approval from the Food and Drug Administration ...
Suscribirse a:
Comentarios (Atom)